Form 4: Dermata Therapeutics Director Acquires Stock Options

David F. Hale, a director at Dermata Therapeutics, acquired 5,000 stock options on January 13, 2025.

Summary

• David F. Hale, a director of Dermata Therapeutics, acquired 5,000 stock options on January 13, 2025.
• The options have an exercise price of $1.38 per share.
• The options vest in twelve equal monthly installments starting one month after the grant date, subject to continued service.
• The options expire on January 12, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction, which is generally positive as it aligns director interests with shareholders. It is not a major event but is a normal part of corporate governance.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard transaction for a director of a public company, often used as part of their compensation package and to align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice across the industry.
• The vesting schedule of 12 months is also a typical arrangement.
• The exercise price of $1.38 is specific to Dermata Therapeutics and would need to be compared to the current share price to assess its value.

Stakeholder Impact

• The stock option grant could be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, Dermata Therapeutics, director, insider trading, equity, DRMA